International reliance route for medical devices in the UK: proposed status

1. Key takeaways

The United Kingdom is building an international reliance channel under which devices already approved in comparable regulatory jurisdictions such as Australia, Canada and the United States would receive simplified review. The concept has been folded into the proposed premarket statutory instrument, referred to in the industry as the draft Medical Devices (Amendment) Regulations 2026. As of the verification date, that draft has not been brought into force, and the operative British obligations remain those in the current text of SI 2002/618. No manufacturer can cite the reliance concept today as a basis for placing a device, and any service provider who claims otherwise should be asked for the statutory reference, which does not exist.

In addition, the separate proposal for a reliance route limited to devices whose UK classification sits higher than their EU classification was not supported by a majority of respondents in the government response published on 21 October 2026. Its rejection narrows the likely final shape of the reliance provisions and signals that the government is unwilling to carry complexity that respondents judged disproportionate.

2. Legal basis

• Currently operative text: UK MDR 2002 (SI 2002/618, as amended), which contains no enacted international reliance provision of any kind.
• GOV.UK consultation response titled ‘Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices’ (published 21 October 2026): records that the third proposal did not attract majority support.
• Proposed status: the draft premarket statutory instrument (as of the verification date there is no enacted text passed by Parliament that can be cited).

3. Expert insights

Insight one: a government response and enacted law must be kept strictly apart. A government response is a statement of policy intention; what changes corporate obligations is the statutory instrument itself. Until the instrument is made and commences, any claim that international reliance is already available is simply false. GRZAN’s verification did not accept secondary-source information about specific effective months, because such claims circulated widely and none could be traced to an enacted instrument. The discipline of demanding a statutory reference before updating a compliance calendar is what separates a controlled regulatory function from rumour-driven planning.

Insight two: the proposal bundles several structural reforms. According to public information, the direction of the draft includes: international reliance, mandatory UDI, alignment of the IVD classification rules with the IMDRF framework, implant cards, strengthened technical documentation requirements, and traceability for custom-made devices. If enacted as a package, this would be the largest premarket reform in the United Kingdom since its departure from the European Union. The breadth matters for planning: even the reliance elements arrive embedded in a wider set of new duties, so the total implementation load on a manufacturer will exceed the reliance benefit alone.

Insight three: reliance is not exemption from review. Under the definitions used by the World Health Organization, which the British consultation documents also cite, recognition means accepting another authority’s regulatory decision as one’s own, whereas reliance means giving significant weight to the other authority’s assessment while remaining independently responsible for the national decision. Even if the reliance route is enacted, the British regulator retains the space to form its own judgement and to attach additional conditions. Marketing the future route as automatic market authorisation is therefore inaccurate, and distributors who are promised it should be corrected early.

4. Practical recommendations

GRZAN recommends placing international reliance on a watch list rather than a production plan. For products holding FDA, TGA or Health Canada approvals, the technical summaries and approval documents can be pre-organised now, so that a future simplified review can be served from existing files within days rather than months. That preparation is cheap, reversible and useful for other purposes as well. What should not be done is to postpone the current UKCA or CE pathway arrangements on the strength of the reliance concept, because the concept carries no legal force and the implementing timetable is unknown, so a plan built on it has no firm footing and a missed British window cannot be recovered retrospectively.

The pre-organisation work itself deserves a short specification. For each eligible product, the package should contain: the approval letter or certificate from the reference regulator, the current technical summary, the classification rationale, and a short note mapping the foreign approval evidence to the elements a British reviewer would expect to see. Packages kept in this form age slowly, need only light refreshes when the underlying approval changes, and can be repurposed for distributor due diligence or acquisition reviews without additional effort, so the preparation cost is spread across several uses rather than carried by the reliance route alone.

The watch list should be reviewed at a fixed cadence, for example quarterly, against the parliamentary progress of the draft instrument, and each review should record whether anything material has changed. Owners of the watch list should be explicitly named so that the monitoring does not silently lapse after personnel changes, which is the most common way such mechanisms die.

When the instrument eventually appears, the first reading should focus on three questions in order: whether the reliance provisions apply to the product’s class, what evidence of the foreign approval they demand, and what residual review the regulator retains. Answering those three questions quickly at enactment, from a package that already exists, is the realistic way to convert a future policy into an early market advantage without having compressed the current pathway work in the meantime.

5. Verification checklist

• □ It has been confirmed that international reliance currently has no enacted legal basis
• □ Policy intention and enacted legislation have been distinguished
• □ Market entry has been arranged under the current SI 2002/618
• □ A monitoring mechanism for the draft instrument has been established
• □ Products holding Australian, Canadian or United States approvals have pre-organised technical summaries ready

Regulatory information verified as of 29 October 2026.

• Appointment of a UK responsible person (UKRP) and support for signing the letter of authorisation
• MHRA registration (DORS): end-to-end filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee estimates
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) options
• Post-market surveillance (PMS) system build, PMSR/PSUR preparation and vigilance reporting
• Emergency handling of serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory change and compliance gap assessments

GRZAN supports manufacturers entering the United Kingdom with UKCA registration pathways and classification strategy, from first route analysis through to registration and post-market obligations. For a structured review of your product portfolio, contact info@grzanglobal.com.